• Dacomitinib (PF-00299804) Research Workflows

  2026-08-27

  Dacomitinib (PF-00299804) provides a durable way to dissect EGFR, HER2, and HER4 signaling in resistant cancer models. This workflow-oriented guide also shows how to connect pan-HER perturbation with mitochondrial ferroptosis assays inspired by recent colorectal cancer research, without overstating the evidence.

• Degarelix Acetate: Interpreting Endocrine Assays

  2026-08-27

  Degarelix acetate is a selective GnRH receptor antagonist for dissecting receptor binding, pituitary hormone regulation, and androgen-deprivation biology. This guide moves beyond protocol recipes to explain how assay timing, pathway-level readouts, and translational limits shape defensible prostate cancer research conclusions.

• MLKL Polymerization Promotes Lysosomal Permeabilization

  2026-08-26

  The reference study identifies lysosomal membrane permeabilization as a central execution step in necroptosis driven by polymerized MLKL. Using live-cell imaging, lysosomal tracking, MLKL-domain experiments, and cathepsin B perturbation, the authors connect MLKL polymerization to lysosomal rupture, cytosolic protease release, and loss of cell viability.

• ARB Reprograms Armored and Cold Tumors

  2026-08-26

  The reference study identifies AGTR1 as a stromal and tumor-associated vulnerability in collagen-rich, immune-excluded tumors that respond poorly to immune checkpoint blockade. Its integrated transcriptomic, mechanistic, animal, cohort, and meta-analytic evidence suggests that angiotensin receptor blockade can remodel the tumor microenvironment and improve checkpoint therapy sensitivity.

• Toremifene and the STIM1 Axis in Prostate Cancer

  2026-08-25

  Toremifene offers a practical way to interrogate estrogen receptor biology while broadening prostate cancer research toward calcium-dependent metastatic mechanisms. By pairing selective estrogen-receptor modulation with STIM1, calcium-entry, and invasion readouts, researchers can test a translational hypothesis without overstating an interaction that remains to be established.

• Ionomycin Free Acid for Calcium-to-FAK Studies

  2026-08-25

  Ionomycin free acid provides a controllable calcium ionophore workflow for separating acute intracellular calcium increase from downstream FAK stability and adhesion phenotypes. This guide translates the FAISL–FAK findings in triple-negative breast cancer into practical dose, timing, control, and troubleshooting strategies.

• Thymoquinone in Cardiotoxicity Research

  2026-08-24

  Thymoquinone provides a practical probe for studying doxorubicin-induced cardiac injury through oxidative stress, Nrf2/HO-1 signaling, mitochondrial damage, and ferroptosis-related endpoints. This workflow translates a mouse study into reproducible formulation, dosing, assay-selection, and troubleshooting strategies for preclinical research.

• CRTC-CREB Senses Proteotoxic Stress in Drosophila

  2026-08-23

  The reference study identifies the CRTC-CREB axis as a stress-responsive transcriptional system that links proteasome inhibition to ROS and JNK signaling in Drosophila. Its experiments suggest that strengthening CRTC-CREB activity can improve proteostasis and reduce Huntington’s disease-related protein aggregation, while also clarifying how MLN2238 can function as a mechanistic trigger in proteotoxic-stress studies.

• Coumestrol in RA: ER Signaling to Ferroptosis

  2026-08-22

  A translational perspective on Coumestrol as a phytoestrogen estrogen receptor antagonist, linking estrogen receptor pharmacology with PMAIP1-dependent ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody

  2026-08-21

  Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat IgG primary antibodies in ICC/IF, frozen and paraffin tissue staining, flow cytometry, and fluorescence-based ELISA. It should not be used as a universal secondary antibody, with non-goat primary antibodies, or in enzyme-substrate ELISA formats without separate validation.

• Tofacitinib (CP-690550): From JAK to Immune Repair

  2026-08-21

  A translational perspective on how Tofacitinib and CP-690550 move beyond cytokine suppression to reshape STAT5-driven macrophage inflammation, mitochondrial dysfunction, and immune-metabolic research strategy.

• Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer

  2026-08-20

  Mei et al. show that hyperthermia lowers BRCA2 protein abundance and functionally weakens homologous recombination in BRCA2-proficient ovarian carcinoma. This creates a therapeutic vulnerability to Niraparib, providing preclinical support for combining controlled hyperthermia with PARP inhibition beyond genetically BRCA-deficient tumors.

• Annexin V-PE Reagent in CAR-T Cell Fate Mapping

  2026-08-20

  Annexin V-PE Reagent can do more than identify dying cells: it can help map target-cell killing, effector-cell fratricide, and assay-state transitions in CD38 CAR-T research. This article connects PS biology with structure-guided CAR affinity tuning while defining practical limits and controls.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance

  2026-08-19

  This study identifies RCN2 as a mechanistic driver of esophageal squamous cell carcinoma metastasis and cisplatin resistance. It connects RCN2 to UBR5-dependent PPP2CA degradation and PI3K-AKT activation, providing a molecular framework for interpreting treatment failure and testing pathway-directed interventions.

• Resveratrol for SIRT1-Driven Neuroprotection

  2026-08-18

  Build a mechanistically grounded Resveratrol neuroprotection assay around SIRT1, mitochondrial biogenesis, and apoptosis rather than relying on viability alone. This workflow connects N2a prion-peptide injury models with practical formulation, controls, endpoint selection, and troubleshooting guidance.

443 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page